DOI: 10.1097/00004850-200303000-00001 Spiering BA, Kraemer WJ, Vingren JL, et al
Key Benefits Observed in Clinical Trials Treatment of Erythropoietic Protoporphyria (EPP): MT-1 (Afamelanotide) is FDA-approved for use in patients with EPP, a rare genetic disorder that causes extreme photosensitivity, leading to severe pain and skin damage upon light exposure
Even simple physical tasks may feel disproportionately draining because cells cannot generate adequate ATP
The majority are of mild to moderate severity and of short duration. The spokesperson added that Novo Nordisk has completed clinical studies conducted in-house with up to 2.5 years of study duration. Patient safety is of utmost importance to Novo Nordisk and we are continuously collecting safety data on our marketed GLP-1 RAs and collaborating closely with authorities to ensure patient safety, the rep said
Similarly, renal clearance appears more significant for the elimination of already inactivated GLP-1
Concerns with radioactive iodine include expense and isolation during treatment for about a week